Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: hepatitis c + bile acid + acid  Related to the article below (Last Update: 5/5/2008)

Bile Duct Congestion Can Lead to Intestinal Diseases and Liver ...
Natural News.com, AZ - May 2, 2008
When acid food (chyme) from the stomach enters the duodenum, it combines first with bile and pancreatic juice, and then with intestinal juice. ...
Source: Google News

A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. -
S Takano, Y Ito, O Yokosuka, M Ohto, K Uchiumi, K … - Hepatology, 1994 - ncbi.nlm.nih.gov
... on liver function tests and on bile acid metabolism was investigated in a
multi-center randomized controlled dose study for chronic hepatitis C. Twenty, 18 ...

… of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis. -
M Podda, C Ghezzi, PM Battezzati, A Crosignani, M … - Gastroenterology, 1990 - ncbi.nlm.nih.gov
... serum liver enzymes and bile acids in chronic hepatitis. Podda M, Ghezzi C, Battezzati
PM, Crosignani A ... Hydrophobic bile acids have been shown to be hepatotoxic ...

The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity -
JL Staudinger, B Goodwin, SA Jones, D Hawkins- … - Proceedings of the National Academy of Sciences, 2001 - National Acad Sciences
... Home page KO Chang and DW George Bile Acids Promote the Expression of Hepatitis
C Virus in Replicon-Harboring Cells J. Virol., September 15, 2007; 81(18): 9633 ...

Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I … -
… R Sumpter Jr, YM Loo, CL Johnson, C Wang, PM Fish … - Proceedings of the National Academy of Sciences, 2005 - National Acad Sciences
... MICROBIOLOGY Control of antiviral defenses through hepatitis C virus disruption
of retinoic acid-inducible gene-I signaling. Eileen ...

A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane … -
CM Rodrigues, G Fan, X Ma, BT Kren, CJ Steer - Journal of Clinical Investigation, 1998 - pubmedcentral.nih.gov
... Ghezzi C, Battezzati PM, Crosignani A, Zuin M, Roda A. Effects of ursodeoxycholic
acid and taurine on serum liver enzymes and bile acids in chronic hepatitis. ...

… of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment -
M Leuschner, CF Dietrich, T You, C Seidl, J Raedle … - British Medical Journal, 2000 - gut.bmj.com
... was there a significant increase in the more apolar bile acids chenodeoxycholic
acid, deoxycholic acid, or lithocholic acid. Hepatitis B and C markers (anti-HBs ...

Ursodeoxycholic acid in cholestasis: Potential mechanisms of action and therapeutic applications -
U Beuers, JL Boyer, G Paumgartner - Hepatology, 1998 - doi.wiley.com
... paucity of the intrahepatic bile ducts (Alagille ... treatment of chronic viral hepatitis
C. In summary ... Gallstone dissolution with ursodeoxycholic acid in patients ...

Hepatic basolateral sodium-dependent-bile acid transporter expression in two unusual cases of … -
BL Shneider, VL Fox, KB Schwarz, CL Watson, M … - Hepatology, 1997 - doi.wiley.com
... specific defect in primary bile acid synthesis. ... amino acids, serologies for
hepatitis C virus, hepatitis B virus, hu- Liver Biopsies. ...

Factors predictive of the response to interferon in patients with chronic hepatitis C. -
… P Giral, A Loria, T Andreani, C Legendre, R Poupon - J Hepatol, 1994 - ncbi.nlm.nih.gov
... treatment, in 75 patients with chronic hepatitis C virus treated ... alkaline phosphatase
activities, bilirubinemia, serum bile acid concentrations, prothrombin ...

Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. -
K NAKAMURA, M YONEDA, S YOKOHAMA, K TAMORI, Y SATO … - Journal of Gastroenterology & Hepatology, 1998 - pt.wkhealth.com
... Simon C. Autoimmune chronic active hepatitis in postmenopausal ... S, Fischer S, Talos
C, Reichen J ... oxidative mitochondrial metabolism from bile acid toxicity: dose ...

Source: Google Scholar

Bile acid may improve hepatitis C therapy response

Last Updated: 2007-12-11 13:05:32 -0400 (Reuters Health)

By David Douglas

NEW YORK (Reuters Health) - A bile acid - called ursodeoxycholic acid -- may improve response to treatment in patients with chronic hepatitis C virus (HCV) who don't respond to standard therapy with interferon and ribavirin, Japanese researchers report in the medical journal Gut.

Ursodeoxycholic acid is a secondary bile acid that breaks down fat, and reduces the amount of cholesterol produced by the liver and absorbed by the intestines. It also helps break down cholesterol that has formed into gall stones and increases bile flow in patients with primary biliary cirrhosis.

Ursodeoxycholic acid therapy, which reduces levels of a type of enzyme (aminotransferase), may slow the progression of liver fibrosis and prevent the development of liver cancer, Dr. Masao Omata told Reuters Health.

Omata, of the University of Tokyo Graduate School of Medicine, and colleagues note that 1b is the most common HCV strain in Japan and can be resistance even to combination therapy. Only about 50 percent of patients with this HCV type have a sustained response to treatment.

To investigate whether the addition of ursodeoxycholic acid can improve treatment results, the researchers studied 596 patients who had elevated levels of the liver enzyme alanine aminotransferase (ALT). The patients were randomly assigned to receive one of three daily doses of ursodeoxycholic acid for 24 weeks.

ALT, as well as two additional liver enzymes, aspartate aminotransferase (AST) and gamma-glutamyl transpeptidase (GGT), decreased at week 4 and then remained constant during drug administration.

Changes in ALT and AST did not differ in the patients who received the two higher doses -- 600 milligrams (mg) or 900 mg -- but GCT was significantly lower in the 900 mg group. In patients with initial GCT levels exceeding 80 IU/L who received 900 mg, ALT also showed a significant decrease.

However, there was no change in blood levels of HCV in any of the groups. Overall, 19.1 percent of patients reported adverse effects, but there were no differences in adverse effects among three groups.

Based on the findings, "there is not sufficient data to advise ursodeoxycholic acid treatment in hepatitis C," co-author of an accompanying editorial Dr. Raoul Poupon of Universite Pierre and Marie Curie, Paris told Reuters Health.

SOURCE: Gut, December 2007.

.

Copyright © 2007 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.